Spencer Gibson

Professor

University of Alberta

Canada

Research Interests

Explore related searches

Professors in Canada Professors in Cancer Biology Cancer Biology professors in Canada

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Spencer Gibson is a Professor at the University of Alberta, located in Canada. His research primarily focuses on chronic lymphocytic leukemia, drug resistance mechanisms, and the tumor microenvironment. Recent articles by Professor Gibson include studies on the role of saturated fatty acids in lymphatic endothelial cells, novel therapeutic approaches for leukemia, and the relationship between immune factors and clinical outcomes in cancer.

Articles (14)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (6)

David N. Brindley

University of Alberta

CANADA

View details

Hasan Uludag

University of Alberta

CANADA

View details

Sabine Hombach-Klonisch

Professor

University of Manitoba

CANADA

View details

Versha Banerji

University of Manitoba

CANADA

View details

Franco Vizeacoumar

Associate Professor

University of Saskatchewan

CANADA

View details

Kathleen Decker

University of Manitoba

CANADA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Spencer Gibson

Research Interests

Explore related searches

Contact this professor

About

Articles (14)

ATM inhibition decreases ERK activation and is synergistic with ibrutinib in primary chronic lymphocytic leukemia cells

Saturated fatty acids induce lipotoxicity in lymphatic endothelial cells contributing to secondary lymphedema development

Suppressing t(4;11) Acute Leukemia by Lipopolymer Nanoparticle Delivery of siRNA Targeting KMT2A::AFF1 with Enhanced Extrahepatic Delivery

Breast Tumor Metastasis and Its Microenvironment: It Takes Both Seed and Soil to Grow a Tumor and Target It for Treatment

Venetoclax inhibits autophagy in chronic lymphocytic leukemia cells

Clinical Outcomes in a Large Canadian Centralized CLL Clinic Based on Treatment and Molecular Factors over a Decade

Elevated expression of interleukin 16 in chronic lymphocytic leukemia is associated with disease burden and abnormal immune microenvironment.

A novel method to investigate drug resistance in the chronic lymphocytic leukemia (CLL) microenvironment: Analysis of CLL Cellular Environment and Response (ACCER).

DNA-PK hyperactivation occurs in deletion 11q chronic lymphocytic leukemia and is both a biomarker and therapeutic target for drug-resistant disease.

Prostate Cancer Cells Are Sensitive to Lysosomotropic Agent Siramesine through Generation Reactive Oxygen Species and in Combination with Tyrosine Kinase Inhibitors.

Patterns and predictors of referral to the specialized chronic lymphocytic leukemia clinic in Manitoba, Canada.

Tumor Suppressing Subtransferable Candidate 4 Expression Prevents Autophagy-Induced Cell Death Following Temozolomide Treatment in Glioblastoma Cells.

Real world risk of infusion reactions and effectiveness of front-line obinutuzumab plus chlorambucil compared with other frontline treatments for chronic lymphocytic leukemia.

Misoprostol treatment prevents hypoxia-induced cardiac dysfunction through a 14-3-3 and PKA regulatory motif on Bnip3.

Collaborators (6)

David N. Brindley

Hasan Uludag

Sabine Hombach-Klonisch

Versha Banerji

Franco Vizeacoumar

Kathleen Decker

Make your next move.